Elanco has launched Zenrelia (ilunocitinib), a once-daily tablet for pruritic dogs with atopic dermatitis, flea allergy dermatitis, food allergies and contact allergies, which the company claims is 50% more effective than Apoquel.

Zenrelia is a new JAK inhibitor which Elanco says provides visible itch relief which lasts 24 hours, from the first dose.1

The company points to a head-to-head study with over 330 dogs across 25 vet clinics, in which Zenrelia was shown to get nearly 50% more itchy dogs back to normal than Apoquel (oclacitinib).1

Elanco says its once-daily dosing may also improve treatment compliance over twice-daily alternatives.

The company also says that Zenrelia has a cost benefit too, presumably meaning it's cheaper than alternatives.

Zenrelia can be given long term with commonly used medications, including vaccines, antibiotics, parasiticides and NSAIDs.

Elanco UK & Ireland General Manager Matthew Frost said: “With this treatment, we’re looking at happier dogs and their owners, and a more rewarding experience for vets.” 

www.zenrelia.co.uk

Reference

  1. Forster S et al. Vet Dermatol. 2025 Apr;36(2):165-176.

PS: Whilst you're here, take a moment to see our latest job opportunities for vet nurses.